News|Videos|January 20, 2023
BTK Inhibitors for the Treatment of Relapsed CLL
Seema Ali Bhat, MD, explains the SEQUOIA trial and the BTK inhibitor zanubrutinib for the frontline treatment of CLL, and Alexey Danilov, MD, PhD, describes the ASCEND trial that led to the approval of acalabrutinib for relapsed CLL.
Advertisement
Episodes in this series
Advertisement
Related to this article
Experts discuss why the convenience of the all-oral decitabine/cedazuridine plus venetoclax regimen does not reduce the need for close monitoring in AML.
The approval expands the indication of pirtobrutinib to patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma with no known 17p deletion.
Advertisement
Advertisement
Trending on CancerNetwork
1
BNT113/Pembrolizumab Misses PFS End Point in HPV16+ Head and Neck Cancer
2
RYZ101 Improves Progression-Free Survival in Previously Treated GEP-NETs
3
How Might IMiD Holding Therapy Impact Outcomes in R/R Multiple Myeloma?
4
Teclistamab Vs Talquetamab After Relapse on CAR T-Cell Therapy in Multiple Myeloma
5